“It is a recognition of the group’s drug development expertise and our ability to translate innovation into solutions for real-world medical challenges," says executive chairman and CEO Eddy Lee.
iX Biopharma has been awarded a US$40.95 million development contract by the US Department of Defense to fund the development of Wafermine®, its patented sublingual ketamine wafer for the treatment of acute moderate to severe pain.
The contract was awarded to iX Biopharma under a sole-source procurement process and represents a significant international validation of Singapore-developed pharmaceutical innovation, the company says.
